📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The CTD table of contents for the whole submission — the map of Modules 2 through 5.
Why it exists. A marketing application is thousands of pages; reviewers navigate it through this standardized ICH table of contents. It shows how the dossier is organized and where each report lives.
How it is produced here. It contains no new data. It is a distillation — it gathers, summarizes, and cross-references the underlying study reports and datasets into the shorter form a regulator reads first.
Format & governing standard. ICH M4 (CTD)
| Field | Value |
|---|---|
| Document ID | M21 |
| Version | 1.0 |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Standard | ICH M4 (CTD) |
| Confidentiality | Confidential — portfolio use |
Table of Contents for CTD Modules 2–5 (and Module 1 regional). A navigable, hyperlinked version is generated at
outputs/ectd/0000/index.html.
| Version | Date | Author | Summary |
|---|
No comments yet. Be the first to say something!
| 1.0 | 2026-06-29 | Regulatory | Initial CTD ToC |
outputs/ectd/0000/index.html Supporting section and planning/master_document_index.md.